🟢 New in Current Filing Failure to effectively or efficiently complete or manage critical business processes could have unforeseen consequences. 🔒

🟢 New in Current Filing Risk Factors 🔒

🟢 New in Current Filing Our business could be affected by activist shareholders. 🔒

🟢 New in Current Filing products and raw materials available to us and are subject to fluctuations in costs, availability and regulatory risk associated with these products and raw materials. 🔒

🟢 New in Current Filing PeriodTotal Numberof SharesPurchased (1)Average Price Paid per ShareTotal Number of SharesPurchasedas Part of Publicly Announced Programs (2)ApproximateDollar Value ofShares That MayYet be PurchasedUnder the Programs (3)(in millions)April 2023234 $79.43 — $1,243 May 2023137 83.79 — 1,243 June 20234,588,337 87.18 4,588,208 4,343 Total4,588,708 $87.18 4,588,208 $4,343 🔒

🟢 New in Current Filing Divestitures 🔒

🟢 New in Current Filing Opioid Lawsuits and Investigations 🔒

🟢 New in Current Filing Shareholder Derivative Litigation 🔒

🟢 New in Current Filing Notes to Financial Statements 🔒

🟢 New in Current Filing Employee Retirement Savings Plans 🔒

🟢 New in Current Filing Schedule II - Valuation and Qualifying Accounts 🔒

🟢 New in Current Filing Information About Our Executive Officers 🔒

🟢 New in Current Filing Directors and Corporate Governance 🔒

🟢 New in Current Filing Directors, Executive Officers, and Corporate Governance 🔒

🟢 New in Current Filing Exhibits, Financial Statement Schedules 🔒

🔴 No Match in Current Filing Our Pharmaceutical segment’s profit margin could be adversely affected by changes in industry or market dynamics that we are not able to accurately predict. 🔒

🔴 No Match in Current Filing Consolidation in the U.S. healthcare industry may negatively impact our results of operations. 🔒

🔴 No Match in Current Filing Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency and other 🔒

🔴 No Match in Current Filing We have been and expect to continue to be negatively affected by the ongoing COVID-19 pandemic. 🔒

🔴 No Match in Current Filing PeriodTotal Numberof SharesPurchased (1)Average Price Paid per ShareTotal Number of SharesPurchasedas Part of Publicly Announced Programs (2)ApproximateDollar Value ofShares That MayYet be PurchasedUnder the Programs (3)(in millions)April 2022608,582 $65.80 607,823 $2,743 May 2022216 56.93 — 2,743 June 2022253 52.93 — 2,743 Total609,051 $65.79 607,823 $2,743 🔒

🔴 No Match in Current Filing Pharmaceutical Segment Information Technology Initiative 🔒

🔴 No Match in Current Filing Product Liability Lawsuits 🔒

🔴 No Match in Current Filing Opioid Lawsuits 🔒

🔴 No Match in Current Filing Divestitures 🔒

🔴 No Match in Current Filing Acquisitions 🔒

🔴 No Match in Current Filing Notes to Financial Statements 🔒

🔴 No Match in Current Filing Other Financing Arrangements 🔒

🔴 No Match in Current Filing Notes to Financial Statements 🔒

🔴 No Match in Current Filing Opioid Lawsuits and Investigations 🔒

🔴 No Match in Current Filing Specialty Solutions DOJ Investigation 🔒

🔴 No Match in Current Filing Assets and (Liabilities) Measured on a Nonrecurring Basis 🔒

🟡 Modified Tax Effects of Self-Insurance Pre-Tax Loss 🔒

🟡 Modified Our business and results of operations could be adversely affected if we experience a material cyber-attack or other systems breach. 🔒

🟡 Modified Fair Value Measurements 🔒

🟡 Modified Goodwill and Other Intangible Assets 🔒

🟡 Modified Commodity Price Risk Management 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Antitrust Litigation Proceeds 🔒

🟡 Modified Risk Factors 🔒

🟡 Modified Critical Audit Matters 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Unrecognized Tax Benefits 🔒

🟡 Modified Risk Factors 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified challenges to our tax positions. 🔒

🟡 Modified 12. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. 🔒

🟡 Modified Long-Term Debt 🔒

🟡 Modified Investments 🔒

🟡 Modified Definition and Limitations of Internal Control Over Financial Reporting 🔒

🟡 Modified Net deferred income tax liability 🔒

🟡 Modified Net Investment Hedges 🔒

🟡 Modified Properties and Legal Proceedings 🔒

🟡 Modified Fair Value of Financial Instruments 🔒

🟡 Modified Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency and other risks could disrupt our global operations or negatively impact our financial results. 🔒

🟡 Modified 11. Shareholders' Equity/(Deficit) 🔒

🟡 Modified Our business is subject to other rigorous quality, regulatory and licensing requirements. 🔒

🟡 Modified New York Opioid Stewardship Act 🔒

🟡 Modified Our business and operations depend on the proper functioning of information systems, critical facilities and distribution networks and could be negatively impacted by events outside of our control. 🔒

🟡 Modified Restricted Share Units 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Self-Insurance 🔒

🟡 Modified Tax Effects of Goodwill Impairment Charges 🔒

🟡 Modified Fair Value Hedges 🔒

🟡 Modified Risk Factors 🔒

🟡 Modified Our Pharmaceutical segment’s profit margin could be adversely affected by changes in industry or market dynamics that we are not able to accurately predict. 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Inventories 🔒

🟡 Modified Deferred Income Taxes 🔒

🟡 Modified Consolidated Statements of Shareholders' Equity/(Deficit) 🔒

🟡 Modified Accumulated Other Comprehensive Loss 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Risk Factors 🔒

🟡 Modified Third-Party Returns 🔒

🟡 Modified Opioid-related legal proceedings and the National Opioid Settlement Agreement we have entered into could have additional or unexpected negative effects on our results of operations or business. 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Revenue Recognition 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Property and Equipment 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Changes in Internal Control Over Financial Reporting 🔒

🟡 Modified Risk Factors 🔒

🟡 Modified Sales Returns and Allowances 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified 6. Long-Term Obligations and Other Short-Term Borrowings 🔒

🟡 Modified Risk Factors 🔒

🟡 Modified Five Year Performance Graph 🔒

🟡 Modified Vendor Reserves 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Consolidated Statements of Comprehensive Income/(Loss) 🔒

🟡 Modified Interest Rate Risk Management 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Legal proceedings could adversely impact our cash flows or results of operations. 🔒

🟡 Modified Economic (Non-Designated) Hedges 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Consolidated Statements of Cash Flows 🔒

🟡 Modified Our goodwill or other long-lived assets could be impaired, which could require us to record additional significant charges to earnings in accordance with generally accepted accounting principles. 🔒

🟡 Modified Other Civil Litigation 🔒

🟡 Modified Financial Statements and Supplementary Data 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Income Taxes 🔒

🟡 Modified Other Financing Arrangements 🔒

🟡 Modified 13. Segment Information 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Legal Proceedings 🔒

🟡 Modified Interest Rate, Currency and Commodity Risk 🔒

🟡 Modified Consolidation in the U.S. healthcare industry may negatively impact our results of operations. 🔒

🟡 Modified Our results of operations could be adversely impacted if we fail to manage and complete divestitures. 🔒

🟡 Modified Other Intangible Assets 🔒

🟡 Modified Earnings/(Loss) before Income Taxes and Provision for/(Benefit From) Income Taxes 🔒

🟡 Modified Net earnings/(loss) attributable to Cardinal Health, Inc. 🔒

🟡 Modified Segment Profit 🔒

🟡 Modified Major Customers 🔒

🟡 Modified Currency Exchange Risk Management 🔒

🟡 Modified Share-Based Compensation 🔒

🟡 Modified Consolidated Balance Sheets 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Effective Tax Rate 🔒

🟡 Modified Performance Share Units 🔒

🟡 Modified 4. Goodwill and Other Intangible Assets 🔒

🟡 Modified Translation of Foreign Currencies 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified 14. Share-Based Compensation 🔒

🟡 Modified Assets Held for Sale 🔒

🟡 Modified Shareholder Securities Litigation 🔒

🟡 Modified Notes to Financial Statements 🔒

🟡 Modified Amortization and Other Acquisition-Related Costs 🔒

🟡 Modified 3. Restructuring and Employee Severance 🔒

🟡 Modified Consolidated Statements of Earnings/(Loss) 🔒

🟡 Modified Uncertain Tax Positions 🔒

🟡 Modified Cash Flow Hedges 🔒

🟡 Modified Loss Contingencies 🔒

🟡 Modified Our sales and credit concentration is significant. 🔒

🟡 Modified Balance at end of fiscal year 🔒

🟡 Modified Cordis IVC Filter Matters 🔒